COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Peripheral Artery Occlusive Diseases (PAOD) Study - Clinical Assessment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00771797
Recruitment Status : Withdrawn (investigator took study to university hospital duesseldorf)
First Posted : October 13, 2008
Last Update Posted : September 23, 2015
Heinrich-Heine University, Duesseldorf
Information provided by:
RWTH Aachen University

Brief Summary:
To assess the clinical efficacy and to simultaneously explore the underlying molecular mechanisms of the beneficial effects of flavanol-rich cocoa on vascular function diabetic patients with peripheral artery occlusive diseases (PAOD) of the lower extremities will be investigated.

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Dietary Supplement: high dose flavanoids Dietary Supplement: low dose flavanoids Phase 2

Detailed Description:
50 Type 2 diabetics according to the criteria of the American Diabetes Association suffering from PAOD with a pain free walking distance less than 200 m will be enrolled. In a randomized controlled parallel group study the before established novel 5-level approach of vascular diagnostics will be realised. In order to test the hypothesis, whether cocoa rich in flavanols improves vascular function of diabetic PAOD subjects will regularly intake flavanol rich cocoa (group 1: 975 mg/d, n=50 versus group 2: 90 mg/d, n=50) over a period of two months. Clinical endpoints are the Ankle-Brachial-Index, measured by Doppler ultrasound and the pain-free walking distance determined by a treadmill ergometer. All parameters of vascular diagnostic (see 5-level approach above) will be determined before and two month after cocoa ingestion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Study to Assess the Clinical Efficacy of Flavanol-rich Cocoa on Vascular Function in Diabetic Patients With PAOD
Study Start Date : October 2008
Estimated Primary Completion Date : December 2009
Estimated Study Completion Date : December 2009

Arm Intervention/treatment
Experimental: 1
Treatement with low dose flavanoids over 60 days
Dietary Supplement: low dose flavanoids
treatment with flavanoid-low cocoa two times daily over 60 days

Experimental: 2
Treatment with high dose flavanoids over 60 days
Dietary Supplement: high dose flavanoids
flavanoid rich cocoa 2 times daily over 60 days

Primary Outcome Measures :
  1. Vascular function [ Time Frame: before treatment and after 30 and 60 days ]

Secondary Outcome Measures :
  1. pain free walking distance [ Time Frame: before treatment and 30 and 60 days afterwards ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diabetes mellitus type 2 defined by the criteria of the American Diabetes Association

    • Fasted plasma glucose greater than 126 mg/dL
    • Plasma glucose levels greater than 200 mg/dL 2 hours after OGT
    • Casual plasma glucose greater than 200 mg/dL combined with diabetic symptoms.
  2. Endothelial dysfunction defined by FMD <4%
  3. No changes of medication for 2 months
  4. Significant PAOD (level IIb, III)

Exclusion Criteria:

  1. Ejection fraction <30%
  2. Malignoms
  3. Terminal renal failure with hemodialysis
  4. Relevant cardiac arrhythmias
  5. Acute inflammation defined as CRP >0,5 mg/dl
  6. PAOD (level IV)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00771797

Layout table for location information
Heinrich-Heine-University, Düsseldorf
Düsseldorf, Germany, 40225
Sponsors and Collaborators
RWTH Aachen University
Heinrich-Heine University, Duesseldorf
Layout table for investigator information
Principal Investigator: Tienush Rassaf, MD Clinic for Cardiology, University Düsseldorf
Layout table for additonal information
Responsible Party: Heinrich-Heine-University Düsseldorf, Clinic for Cardiology Identifier: NCT00771797    
Other Study ID Numbers: PAOD Study
First Posted: October 13, 2008    Key Record Dates
Last Update Posted: September 23, 2015
Last Verified: September 2015
Keywords provided by RWTH Aachen University:
vascular function
in diabetics with PAOD
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases